This HTML5 document contains 55 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n12http://linked.opendata.cz/resource/drugbank/drug/DB01078/identifier/pharmgkb/
n7http://linked.opendata.cz/resource/drugbank/drug/DB01078/identifier/kegg-drug/
n14http://bio2rdf.org/drugbank:
n6http://linked.opendata.cz/resource/drugbank/drug/DB01078/identifier/drugbank/
admshttp://www.w3.org/ns/adms#
n9http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n3http://linked.opendata.cz/ontology/drugbank/
n4http://linked.opendata.cz/resource/drugbank/property/
n16http://linked.opendata.cz/resource/drugbank/drug/DB01078/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n11http://linked.opendata.cz/resource/atc/
n13http://linked.opendata.cz/resource/drugbank/drug/DB01078/identifier/wikipedia/
n10http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB01078
rdf:type
n3:Drug
n3:description
Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. [PubChem]
n3:group
approved
n3:halfLife
36 hours
n3:indication
For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure.
owl:sameAs
n9:DB01078 n14:DB01078
dcterms:title
Deslanoside
adms:identifier
n6:DB01078 n7:D01240 n12:PA164747478 n13:Deslanoside n16:31468
n3:mechanismOfAction
Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depolarization, shortening the action potential duration, and decreasing the maximal diastolic potential.
n3:synonym
Deslanosidum Desacetyllanatoside C Deacetyllanatoside C Glucodigoxin (3beta,5beta,12beta)-3-{[beta-D-glucopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-2,6-dideoxy-beta-D-ribo-hexopyranosyl]oxy}-12,14-dihydroxycard-20(22)-enolide 3-[(O-beta-D-Glucopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl-(1->4)-O-2,6-dideoxy-beta-D-ribo-hexopyranosyl)oxy]-12,14-dihydroxy-3beta,5beta,12beta-card-20(22)-enolide Deslanosido
n3:toxicity
Symptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block.
n3:proteinBinding
20%
n3:IUPAC-Name
n4:271B61D3-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B61D9-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B61D8-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B61D5-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B61D6-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B61D7-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B61D1-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B61E9-363D-11E5-9242-09173F13E4C5 n4:271B61D2-363D-11E5-9242-09173F13E4C5 n4:271B61CF-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B61D0-363D-11E5-9242-09173F13E4C5
n10:hasATCCode
n11:C01AA07
n3:H-Bond-Acceptor-Count
n4:271B61DF-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B61E0-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B61DA-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B61DB-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B61DD-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B61DC-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B61DE-363D-11E5-9242-09173F13E4C5
n3:absorption
Little absorption from the gastrointestinal tract (40%).
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
17598-65-1
n3:category
n3:Bioavailability
n4:271B61E5-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B61E7-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B61E8-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B61E4-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B61E3-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B61E6-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B61D4-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B61E1-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B61E2-363D-11E5-9242-09173F13E4C5